Jasper Therapeutics Inc. (NASDAQ: JSPR) traded at a new 52-week high today of $17.27. This new high was reached on above average trading volume as 3.5 million shares traded hands, while the average 30-day volume is approximately 904,000 shares.
Jasper Therapeutics Inc. share prices have moved between a 52-week high of $17.27 and a 52-week low of $7.11 and are now trading 116% above that low price at $15.36 per share.
Jasper Therapeutics Inc. is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Jasper Therapeutics Inc. defies analysts with a current price ($15.36) 17.1% above its average consensus price target of $12.74.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Image Sourced from Pixabay
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.